Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
China NT Pharma Group Co., Ltd. ( (HK:1011) ) just unveiled an update.
China NT Pharma Group has secured shareholder approval at its extraordinary general meeting to issue and allot up to 274,751,679 new shares at HK$0.45 each as consideration for acquiring 100% of the issued shares of Junbinxiongdi Limited, Yuehua Limited and Zhong He Qun Lian Limited. This transaction will give the company effective control over approximately 58.11% of Zhejiang Kangyuan Medical Device Co., Ltd., signalling a strategic expansion into the medical device business and potentially strengthening its position in China’s healthcare market through increased vertical integration and diversification of revenue streams.
The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.92 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.
More about China NT Pharma Group Co., Ltd.
China NT Pharma Group Company Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the healthcare and pharmaceutical sector. The group is engaged in pharmaceutical and related medical businesses in mainland China, and its latest corporate actions indicate a growing focus on medical devices through equity acquisitions in the sector.
Average Trading Volume: 344,371
Technical Sentiment Signal: Buy
Current Market Cap: HK$579.9M
See more data about 1011 stock on TipRanks’ Stock Analysis page.